ORIC Pharmaceuticals, Inc.
ORIC
$5.26
-$0.52-9.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.55% | 15.05% | 13.19% | 6.68% | 2.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.99% | 32.80% | 33.84% | 27.92% | 27.68% |
| Operating Income | -28.99% | -32.80% | -33.84% | -27.92% | -27.68% |
| Income Before Tax | -26.96% | -28.60% | -19.68% | -13.19% | -12.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.96% | -28.60% | -19.68% | -13.19% | -12.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.96% | -28.60% | -19.68% | -13.19% | -12.99% |
| EBIT | -28.99% | -32.80% | -33.84% | -27.92% | -27.68% |
| EBITDA | -29.19% | -33.08% | -34.12% | -28.15% | -27.91% |
| EPS Basic | 7.15% | 9.42% | 19.16% | 17.37% | 12.34% |
| Normalized Basic EPS | 7.14% | 9.42% | 14.20% | 12.33% | 7.13% |
| EPS Diluted | 7.15% | 9.42% | 19.16% | 17.37% | 12.34% |
| Normalized Diluted EPS | 7.14% | 9.42% | 14.20% | 12.33% | 7.13% |
| Average Basic Shares Outstanding | 35.64% | 41.13% | 48.18% | 38.71% | 29.63% |
| Average Diluted Shares Outstanding | 35.64% | 41.13% | 48.18% | 38.71% | 29.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
